Influenza A virus hemagglutinin (H9 subtype) (HA)

Influenza A H9N2 hemagglutinin is a major surface glycoprotein of the H9N2 subtype of influenza A virus, which is primarily endemic in poultry but possesses significant zoonotic potential (WHO, 2023). It functions as a class I fusion protein, responsible for binding the virus to host cell surface receptors containing sialic acid and subsequently mediating the fusion of the viral envelope with the host endosomal membrane (UniProt, 2024). The protein is synthesized as a precursor, HA0, which must be cleaved by host proteases into HA1 and HA2 subunits to become infectious (PubMed, PMID: 28834717). Because it is the primary target of the host immune response, it is the central component of influenza vaccines and a key focus for the development of neutralizing monoclonal antibodies (CDC, 2024). Research into H9N2 hemagglutinin is critical due to the virus's role as a genetic reservoir, frequently donating internal genes to other highly pathogenic avian influenza viruses like H5N1 and H7N9 (PubMed, PMID: 24048553). Small molecule inhibitors like Umifenovir target the HA stem region to prevent the conformational changes necessary for fusion (PubMed, PMID: 30655333). Monitoring mutations in the HA protein, particularly those affecting receptor binding specificity, is essential for assessing the pandemic risk posed by circulating H9N2 strains.

Other names

H9 HAHemagglutininHA0HA1HA2Surface glycoproteinH9N2 HA

Inhibition of viral entry by blocking receptor binding or preventing the conformational change required for membrane fusion.